Omega Therapeutics Inc (OMGA) Stock
OMGA is no longer traded. Omega Therapeutics was delisted from the Nasdaq in April 2025.
Prices on this page are historical; the last trade was April 28, 2025 at $0.05.
Omega Therapeutics stock price history
OMGA final trading statistics
- Final close
- $0.05
- Final trading day
- Apr 28, 2025
- Market cap at delisting
- $7.90M
- Shares outstanding
- 55.37M
- Final 52-week range
- $0.01 – $3.00
- Avg. volume (final 3 mo.)
- 8,803,508
- All-time high (split-adj.)
- $29.38 · Oct 2021
- All-time low (split-adj.)
- $0.01 · Mar 2025
- Return since IPO
- -99.7%
- Beta
- 1.64
- Book value / share
- $0.21
- Price / book
- 0.23
Omega Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $3.09M | -$97.4M | -$1.81 |
| FY2022 | $2.07M | -$102.6M | -$2.14 |
| FY2021 | $144.0K | -$69.2M | -$7.37 |
| FY2020 | $0.00 | -$30.2M | -$0.79 |
| FY2019 | $0.00 | -$18.5M | -$0.37 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Omega Therapeutics Inc
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. On February 10, 2025, Omega Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Omega Therapeutics stock FAQ
What happened to Omega Therapeutics stock?
Omega Therapeutics stock was delisted from the Nasdaq. Its final close was $0.05 on April 28, 2025.
Is OMGA stock still trading?
No. OMGA was delisted from the Nasdaq in April 2025 and no longer trades on a U.S. exchange.
What was the last price of OMGA stock?
OMGA closed at $0.05 on its final trading day, April 28, 2025, for a market value of about $7.90M.
What were Omega Therapeutics's revenue and earnings in its last full fiscal year?
Omega Therapeutics reported revenue of $3.09M and net income of -$97.4M in fiscal 2023, its last full year as a public company.
When did Omega Therapeutics go public?
Omega Therapeutics Inc stock began trading on July 30, 2021.